Discussion Overview
The discussion centers on the effectiveness of a third Pfizer vaccine dose in Israel, particularly its reported 86% increase in effectiveness for individuals over 60. Participants explore implications for herd immunity, the methodology behind effectiveness measurements, and the longevity of vaccine-induced immunity.
Discussion Character
- Exploratory
- Technical explanation
- Debate/contested
- Mathematical reasoning
Main Points Raised
- Some participants highlight that the reported 86% effectiveness of the third dose is compared to those who have received two doses, suggesting potential for herd immunity if vaccination rates exceed this threshold.
- One participant presents detailed calculations indicating that herd immunity could be achievable at vaccination rates greater than 86%, although they acknowledge their initial calculations may have been overly pessimistic.
- Another participant questions the clarity of the effectiveness measurement, noting that it is unclear whether the reported figures refer to protection against symptomatic disease or against infection, which could significantly affect conclusions about herd immunity.
- Concerns are raised regarding the durability of immunity, referencing studies on other human coronaviruses that suggest protection against infection diminishes over time, which may undermine long-term herd immunity strategies.
- A participant cites an expert stating that Israel reports a four-fold increase in protection from infection and a five to six-fold increase in protection from hospitalization and severe disease after the third dose, indicating a significant benefit of the booster shot.
Areas of Agreement / Disagreement
Participants express differing views on the implications of the reported effectiveness for herd immunity, the clarity of the data, and the longevity of vaccine-induced immunity. No consensus is reached on these points.
Contextual Notes
Limitations include the lack of clarity on the measurement of effectiveness (symptomatic disease vs. infection) and the potential short-lived nature of immunity based on studies of other coronaviruses.